Apr 25Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidateAccession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Jul 19, 2023Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trialsChief Business Officer appointed at Accession Therapeutics as immune-oncology company prepares for clinical trials in 2024
Jan 4, 2023Accession Therapeutics presented some of the exciting preclinical data for our lead programme Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual...
Nov 29, 2022Biocentury Emerging Company Profile - Accession: precisely targeted oncolytic virusesBent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the...
Nov 29, 2022Accession Therapeutics is attending the J.P. Morgan 41st Annual Healthcare Conference - January 2023We are interested in discussing partnerships, collaborations and investment so please get in touch if you would like to meet us at the...
Nov 21, 2022Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trialsNew Singaporean investor iGlobe Partners backs rapidly developing preclinical pipeline at immunotherapy pioneer’s company